ArticleClinical infectious diseases : an official publication of the Infectious Diseases Society of America2022
Relapse of Plasmodium vivax and Plasmodium ovale Malaria With and Without Primaquine Treatment in a Nonendemic Area.
Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 24 citations in OpenAlex.
- A Systematic Review and Meta-Analysis Exploring Variations in Copper Levels between Individuals with Malaria and Uninfected Controls.Nutrients · 2023Pooled it
- An Increase in ImportedOpen forum infectious diseases · 2026Article
- The profile of imported malaria in Sri Lanka from 2013 to 2023.BMC global and public health · 2026Article
- Recurrent Malaria withTropical medicine and infectious disease · 2025Article
- Malaria: past, present, and future.Signal transduction and targeted therapy · 2025Review
- Analysis of Severe and Relapse Risks of Imported Malaria in Five Provinces of China.The American journal of tropical medicine and hygiene · 2025Article
- Population genomics of Plasmodium ovale species in sub-Saharan Africa.Nature communications · 2024Article
- Recent Advances in the Treatment of Malaria.Pharmaceutics · 2024Review
- Development and longevity of naturally acquired antibody and memory B cell responses against Plasmodium vivax infection.PLoS neglected tropical diseases · 2024Review
- Population genomics ofbioRxiv : the preprint server for biology · 2024Article
- Development of new real-time PCR assays for detection and species differentiation of Plasmodium ovale.PLoS neglected tropical diseases · 2024Article
- Non-falciparum malaria infections in Uganda, does it matter? A review of the published literature.Malaria journal · 2024Review
- Characterization ofMicroorganisms · 2024Article
- Quest for malaria management using natural remedies.Frontiers in pharmacology · 2024Review
- A novel duplex qualitative real-time PCR assay for the detection and differentiation of Plasmodium ovale curtisi and Plasmodium ovale wallikeri malaria.medRxiv : the preprint server for health sciences · 2023Article
- Article
- Systems biology of malaria explored with nonhuman primates.Malaria journal · 2022Review
- Safety and Efficacy of Tafenoquine forTherapeutics and clinical risk management · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe effect of primaquine in preventing Plasmodium vivax relapses from dormant stages is well established. For Plasmodium ovale, the relapse characteristics and the use of primaquine is not as well studied. We set to evaluate the relapsing properties of these 2 species, in relation to primaquine use among imported malaria cases in a nonendemic setting.
methodsWe performed a nationwide retrospective study of malaria diagnosed in Sweden 1995-2019, by reviewing medical records of 3254 cases. All episodes of P. vivax (n = 972) and P. ovale (n = 251) were selected for analysis.
resultsFirst time relapses were reported in 80/857 (9.3%) P. vivax and 9/220 (4.1%) P. ovale episodes, respectively (P < .01). Without primaquine, the risk for relapse was higher in P. vivax, 20/60 (33.3%), compared to 3/30 (10.0%) in P. ovale (hazard ratio [HR] 3.5, 95% confidence interval [CI] 1.0-12.0). In P. vivax, patients prescribed primaquine had a reduced risk of relapse compared to episodes without relapse preventing treatment, 7.1% vs 33.3% (HR 0.2, 95% CI .1-.3). In P. ovale, the effect of primaquine on the risk of relapse did not reach statistical significance, with relapses seen in 2.8% of the episodes compared to 10.0% in patients not receiving relapse preventing treatment (HR 0.3, 95% CI .1-1.1).
conclusionsThe risk of relapse was considerably lower in P. ovale than in P. vivax infections indicating different relapsing features between the two species. Primaquine was effective in preventing P. vivax relapse. In P. ovale, relapse episodes were few, and the supportive evidence for primaquine remains limited.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.